Advanced · No. 02
Compounded Tirzepatide
a dual-incretin once-weekly injection
2.5 MG → 15 MG · 4-week vial supply
First month
$279.99
≈ $9.33 / day
Brand-name Zepbound cash
$1,349
$45 / day
Fig. 01 · Compounded TirzepatideLOT 50087439
a dual-incretin once-weekly injection
2.5 MG → 15 MG · 4-week vial supply
Tirzepatide is the most effective pharmacological weight-management compound ever to clear a phase-3 trial. It engages two appetite hormones — GLP-1 and GIP — rather than one, producing larger and more durable weight loss than any single-agonist GLP-1.
Tirzepatide is a synthetic peptide that simultaneously activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The combined agonism slows gastric emptying, suppresses appetite via central pathways in the hypothalamus, improves insulin sensitivity, and reduces food noise. The dual mechanism is what produces the larger weight-loss effect compared with single-receptor GLP-1s like semaglutide.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 2.5 mg / week | Initiation. Most people feel nothing or mild nausea. |
| Weeks 05–08 | 5.0 mg / week | Appetite suppression becomes noticeable. |
| Weeks 09–12 | 7.5 mg / week | First provider check-in. Re-evaluate fit. |
| Weeks 13–16 | 10.0 mg / week | Most patients hold here as the working dose. |
| Weeks 17+ | 12.5–15 mg / week | Therapeutic maximum, only if tolerated and clinically appropriate. |